Cargando…

Detection and therapy of neuroblastoma minimal residual disease using [(64/67)Cu]Cu-SARTATE in a preclinical model of hepatic metastases

BACKGROUND: A major challenge to the long-term success of neuroblastoma therapy is widespread metastases that survive initial therapy as minimal residual disease (MRD). The SSTR2 receptor is expressed by most neuroblastoma tumors making it an attractive target for molecularly targeted radionuclide t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dearling, Jason L. J., van Dam, Ellen M., Harris, Matthew J., Packard, Alan B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7907331/ https://www.ncbi.nlm.nih.gov/pubmed/33630166 http://dx.doi.org/10.1186/s13550-021-00763-0

Ejemplares similares

An abbreviated therapy-dosimetric equation for the companion diagnostic/therapeutic [(64/67)Cu]Cu-SARTATE
por: Laffon, Eric, et al.
Publicado: (2021)

Harnessing (64)Cu/(67)Cu for a theranostic approach to pretargeted radioimmunotherapy
por: Keinänen, Outi, et al.
Publicado: (2020)

Recent Advances in (64)Cu/(67)Cu-Based Radiopharmaceuticals
por: Krasnovskaya, Olga O., et al.
Publicado: (2023)

Theragnostic (64)Cu/(67)Cu Radioisotopes Production With RFT-30 Cyclotron
por: Lee, Jun Young, et al.
Publicado: (2022)

(64)Cu-ATSM/(64)Cu-Cl(2) and their relationship to hypoxia in glioblastoma: a preclinical study
por: Pérès, Elodie A., et al.
Publicado: (2019)

Theragnostic Radionuclide Pairs for Prostate Cancer Management: (64)Cu/(67)Cu, Can Be a Budding Hot Duo
por: Chhabra, Anupriya, et al.
Publicado: (2022)

Radionuclide Cisternography with [(64)Cu]Cu-DOTA
por: Greiser, Julia, et al.
Publicado: (2023)

Comparison of the Effects of DOTA and NOTA Chelators on (64)Cu-Cudotadipep and (64)Cu-Cunotadipep for Prostate Cancer
por: Lee, Inki, et al.
Publicado: (2023)

Is (70)Zn(d,x)(67)Cu the Best Way to Produce (67)Cu for Medical Applications?
por: Nigron, Etienne, et al.
Publicado: (2021)

Magnetic moment of $^{67}$Ni and $^{67}$Ni $\rightarrow ^{67}$Cu $\beta$-decay
por: Ríkovská, J, et al.
Publicado: (1996)

[(64)Cu]Cu-DOTATATE PET metrics in the investigation of atherosclerotic inflammation in humans
por: Jensen, Jacob K., et al.
Publicado: (2022)

(64)Cu-based Radiopharmaceuticals in Molecular Imaging
por: Zhou, Yeye, et al.
Publicado: (2019)

A feasibility study of the therapeutic application of a mixture of (67/64)Cu radioisotopes produced by cyclotrons with proton irradiation
por: De Nardo, Laura, et al.
Publicado: (2022)

Preclinical Evaluation of a (64)Cu-Based Theranostic Approach in a Murine Model of Multiple Myeloma
por: Métivier, Cassandra, et al.
Publicado: (2023)

Radioimmunoimaging of Liver Metastases with PET Using a (64)Cu-Labeled CEA Antibody in Transgenic Mice
por: Nittka, Stefanie, et al.
Publicado: (2014)

Cyclotron-Based Production of (67)Cu for Radionuclide Theranostics via the (70)Zn(p,α)(67)Cu Reaction
por: Brühlmann, Santiago Andrés, et al.
Publicado: (2023)

(64)Cu-ATSM and (18)FDG PET uptake and (64)Cu-ATSM autoradiography in spontaneous canine tumors: comparison with pimonidazole hypoxia immunohistochemistry
por: Hansen, Anders E, et al.
Publicado: (2012)

Synthesis and evaluation of (64)Cu-radiolabeled NOTA-cetuximab ((64)Cu-NOTA-C225) for immuno-PET imaging of EGFR expression
por: Xu, Xiaoxia, et al.
Publicado: (2019)

Copper Coordination Chemistry of Sulfur Pendant Cyclen Derivatives: An Attempt to Hinder the Reductive-Induced Demetalation in (64/67)Cu Radiopharmaceuticals
por: Tosato, Marianna, et al.
Publicado: (2021)

The somatostatin receptor 2 antagonist (64)Cu-NODAGA-JR11 outperforms (64)Cu-DOTA-TATE in a mouse xenograft model
por: Rylova, Svetlana N., et al.
Publicado: (2018)

Comparison between Three Promising ß-emitting Radionuclides, (67)Cu, (47)Sc and (161)Tb, with Emphasis on Doses Delivered to Minimal Residual Disease
por: Champion, Christophe, et al.
Publicado: (2016)

Effect of Liraglutide on Vascular Inflammation Evaluated by [(64)Cu]DOTATATE
por: Zobel, Emilie H., et al.
Publicado: (2021)

(67)Cu Production Capabilities: A Mini Review
por: Mou, Liliana, et al.
Publicado: (2022)

Effect of intratumoral administration on biodistribution of (64)Cu-labeled nanoshells
por: Xie, Huan, et al.
Publicado: (2012)

Integrated (64)Cu therapy for the peritoneal dissemination of gastrointestinal cancer
por: Kurihara, Hiroaki
Publicado: (2018)

Pilot Study of (64)Cu(I) for PET Imaging of Melanoma
por: Jiang, Lei, et al.
Publicado: (2017)

(64)Cu-DOTATOC PET-CT in Patients with Neuroendocrine Tumors
por: Mirzaei, Siroos, et al.
Publicado: (2019)

Preclinical In Vitro Studies with 3D Spheroids to Evaluate Cu(DDC)(2) Containing Liposomes for the Treatment of Neuroblastoma
por: Hartwig, Friederike, et al.
Publicado: (2021)

Tissue acidosis does not mediate the hypoxia selectivity of [(64)Cu][Cu(ATSM)] in the isolated perfused rat heart
por: Baark, Friedrich, et al.
Publicado: (2019)

Molecular Dynamics Study of the Nanoindentation Behavior of Cu(64)Zr(36)/Cu Amorphous/Crystalline Nanolaminate Composites
por: Wu, Wen-Ping, et al.
Publicado: (2021)

Development of an automated production process of [(64)Cu][Cu (ATSM)] for positron emission tomography imaging and theranostic applications
por: Liu, Tengzhi, et al.
Publicado: (2022)

Intrathecal [(64)Cu]Cu-albumin PET reveals age-related decline of lymphatic drainage of cerebrospinal fluid
por: Sarker, Azmal, et al.
Publicado: (2023)

In vitro and in vivo characterization of [(64)Cu][Cu(elesclomol)] as a novel theranostic agent for hypoxic solid tumors
por: Liu, Tengzhi, et al.
Publicado: (2023)

Hypoxia imaging and theranostic potential of [(64)Cu][Cu(ATSM)] and ionic Cu(II) salts: a review of current evidence and discussion of the retention mechanisms
por: Liu, Tengzhi, et al.
Publicado: (2020)

[(64)Cu]NOTA-pentixather enables high resolution PET imaging of CXCR4 expression in a preclinical lymphoma model
por: Poschenrieder, Andreas, et al.
Publicado: (2017)

In vivo [(64)Cu]CuCl(2) PET imaging reveals activity of Dextran-Catechin on tumor copper homeostasis
por: Parmar, Arvind, et al.
Publicado: (2018)

Impact of [(64)Cu][Cu(ATSM)] PET/CT in the evaluation of hypoxia in a patient with Glioblastoma: a case report
por: Gangemi, Vincenzo, et al.
Publicado: (2019)

Diagnostic Value of Radiolabelled Somatostatin Analogues for Neuroendocrine Tumour Diagnosis: The Benefits and Drawbacks of [(64)Cu]Cu-DOTA-TOC
por: Vahidfar, Nasim, et al.
Publicado: (2022)

Feasibility of Isotope Harvesting at a Projectile Fragmentation Facility: (67)Cu
por: Mastren, Tara, et al.
Publicado: (2014)

Dynamics of Minimal Residual Disease in Neuroblastoma Patients
por: Uemura, Suguru, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_h55bti9fjfa8pfn3rt87886n9k